Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the low dose period.

Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose ...

Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

HealthDay News — International guidelines are presented for the treatment of adults and children with sepsis and septic shock ...

Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

Discontinuing treatment for 0.5 years was associated with increased risk for major adverse cardiovascular events.

The Food and Drug Administration (FDA) has extended the review period for Orca-T in the treatment of patients with ...

Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...